Cargando…
Outcomes of empiric treatment for pediatric tuberculosis, Kampala, Uganda, 2010–2015
BACKGROUND: Childhood tuberculosis (TB) diagnoses often lack microbiologic confirmation and require empiric treatment. Barriers to empiric treatment include concern for poor outcomes and adverse effects. We thus determined the outcomes of empiric TB treatment from a retrospective cohort of children...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489192/ https://www.ncbi.nlm.nih.gov/pubmed/31035984 http://dx.doi.org/10.1186/s12889-019-6821-2 |
_version_ | 1783414770483855360 |
---|---|
author | Wobudeya, Eric Jaganath, Devan Sekadde, Moorine Penninah Nsangi, Betty Haq, Heather Cattamanchi, Adithya |
author_facet | Wobudeya, Eric Jaganath, Devan Sekadde, Moorine Penninah Nsangi, Betty Haq, Heather Cattamanchi, Adithya |
author_sort | Wobudeya, Eric |
collection | PubMed |
description | BACKGROUND: Childhood tuberculosis (TB) diagnoses often lack microbiologic confirmation and require empiric treatment. Barriers to empiric treatment include concern for poor outcomes and adverse effects. We thus determined the outcomes of empiric TB treatment from a retrospective cohort of children at a national referral hospital in Kampala, Uganda from 2010 to 2015. METHODS: Children were diagnosed clinically and followed through treatment. Demographics, clinical data, outcome and any adverse events were extracted from patient charts. A favorable outcome was defined as a child completing treatment with clinical improvement. We performed logistic regression to assess factors associated with loss to follow up and death. RESULTS: Of 516 children, median age was 36 months (IQR 15–73), 55% (95% CI 51–60%) were male, and HIV prevalence was 6% (95% CI 4–9%). The majority (n = 422, 82, 95% CI 78–85%) had a favorable outcome, with no adverse events that required treatment discontinuation. The most common unfavorable outcomes were loss to follow-up (57/94, 61%) and death (35/94, 37%; overall mortality 7%). In regression analysis, loss to follow up was associated with age 10–14 years (OR 2.38, 95% CI 1.15–4.93, p = 0.02), HIV positivity (OR 3.35, 95% CI 1.41–7.92, p = 0.01), hospitalization (OR 4.14, 95% CI 2.08–8.25, p < 0.001), and living outside of Kampala (OR 2.64, 95% CI 1.47–4.71, p = 0.001). Death was associated with hospitalization (OR 4.57, 95% CI 2.0–10.46, p < 0.001), severe malnutrition (OR 2.98, 95% CI 1.07–8.27, p = 0.04), baseline hepatomegaly (OR 4.11, 95% CI 2.09–8.09, p < 0.001), and living outside of Kampala (OR 2.41, 95% CI 1.17–4.96, p = 0.02). CONCLUSIONS: Empiric treatment of child TB was effective and safe, but treatment success remained below the 90% target. Addressing co-morbidities and improving retention in care may reduce unfavorable outcomes. |
format | Online Article Text |
id | pubmed-6489192 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-64891922019-06-05 Outcomes of empiric treatment for pediatric tuberculosis, Kampala, Uganda, 2010–2015 Wobudeya, Eric Jaganath, Devan Sekadde, Moorine Penninah Nsangi, Betty Haq, Heather Cattamanchi, Adithya BMC Public Health Research Article BACKGROUND: Childhood tuberculosis (TB) diagnoses often lack microbiologic confirmation and require empiric treatment. Barriers to empiric treatment include concern for poor outcomes and adverse effects. We thus determined the outcomes of empiric TB treatment from a retrospective cohort of children at a national referral hospital in Kampala, Uganda from 2010 to 2015. METHODS: Children were diagnosed clinically and followed through treatment. Demographics, clinical data, outcome and any adverse events were extracted from patient charts. A favorable outcome was defined as a child completing treatment with clinical improvement. We performed logistic regression to assess factors associated with loss to follow up and death. RESULTS: Of 516 children, median age was 36 months (IQR 15–73), 55% (95% CI 51–60%) were male, and HIV prevalence was 6% (95% CI 4–9%). The majority (n = 422, 82, 95% CI 78–85%) had a favorable outcome, with no adverse events that required treatment discontinuation. The most common unfavorable outcomes were loss to follow-up (57/94, 61%) and death (35/94, 37%; overall mortality 7%). In regression analysis, loss to follow up was associated with age 10–14 years (OR 2.38, 95% CI 1.15–4.93, p = 0.02), HIV positivity (OR 3.35, 95% CI 1.41–7.92, p = 0.01), hospitalization (OR 4.14, 95% CI 2.08–8.25, p < 0.001), and living outside of Kampala (OR 2.64, 95% CI 1.47–4.71, p = 0.001). Death was associated with hospitalization (OR 4.57, 95% CI 2.0–10.46, p < 0.001), severe malnutrition (OR 2.98, 95% CI 1.07–8.27, p = 0.04), baseline hepatomegaly (OR 4.11, 95% CI 2.09–8.09, p < 0.001), and living outside of Kampala (OR 2.41, 95% CI 1.17–4.96, p = 0.02). CONCLUSIONS: Empiric treatment of child TB was effective and safe, but treatment success remained below the 90% target. Addressing co-morbidities and improving retention in care may reduce unfavorable outcomes. BioMed Central 2019-04-29 /pmc/articles/PMC6489192/ /pubmed/31035984 http://dx.doi.org/10.1186/s12889-019-6821-2 Text en © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Wobudeya, Eric Jaganath, Devan Sekadde, Moorine Penninah Nsangi, Betty Haq, Heather Cattamanchi, Adithya Outcomes of empiric treatment for pediatric tuberculosis, Kampala, Uganda, 2010–2015 |
title | Outcomes of empiric treatment for pediatric tuberculosis, Kampala, Uganda, 2010–2015 |
title_full | Outcomes of empiric treatment for pediatric tuberculosis, Kampala, Uganda, 2010–2015 |
title_fullStr | Outcomes of empiric treatment for pediatric tuberculosis, Kampala, Uganda, 2010–2015 |
title_full_unstemmed | Outcomes of empiric treatment for pediatric tuberculosis, Kampala, Uganda, 2010–2015 |
title_short | Outcomes of empiric treatment for pediatric tuberculosis, Kampala, Uganda, 2010–2015 |
title_sort | outcomes of empiric treatment for pediatric tuberculosis, kampala, uganda, 2010–2015 |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489192/ https://www.ncbi.nlm.nih.gov/pubmed/31035984 http://dx.doi.org/10.1186/s12889-019-6821-2 |
work_keys_str_mv | AT wobudeyaeric outcomesofempirictreatmentforpediatrictuberculosiskampalauganda20102015 AT jaganathdevan outcomesofempirictreatmentforpediatrictuberculosiskampalauganda20102015 AT sekaddemoorinepenninah outcomesofempirictreatmentforpediatrictuberculosiskampalauganda20102015 AT nsangibetty outcomesofempirictreatmentforpediatrictuberculosiskampalauganda20102015 AT haqheather outcomesofempirictreatmentforpediatrictuberculosiskampalauganda20102015 AT cattamanchiadithya outcomesofempirictreatmentforpediatrictuberculosiskampalauganda20102015 |